Fig. 4
Antitumor immunity of DEXP&A&N in orthotopic HCC mice. a Flow cytometric analysis to assess the double loading efficiency of two moieties on DEXAFP. DEXP&A&N refer to DEXP47&AFP&N1ND. b Diagram for dosing regimen of DEXP&A&N. DEXAFP or DEXP&A&N (80 μg/mouse) were injected into day-7 orthotopic HCC mice intravenously three times weekly, and tissues were harvested 7 days after last injection. c Dynamic monitoring of tumor growth in orthotopic HCC mice with MRI at different time points. d Measurement of tumor size in orthotopic HCC mice at 21 days after priming (n = 20; one-way ANOVA on ranks). e Flow cytometric and quantitative analysis of GPC3+ tetramer T cells from tumor of orthotopic HCC mice treated with DEXAFP or DEXP&A&N (n = 5; one-way ANOVA post hoc Student–Newman–Keuls test). f Diagram for dosing regimen of DEXP&A&N. DEXAFP or DEXP&A&N (120 μg/mouse) were injected into day-21 orthotopic HCC mice bearing large established tumors intravenously three times weekly, and tissues were harvested 2 weeks after last injection. g Dynamic monitoring of tumor growth in orthotopic HCC mice bearing large established tumors treated with DEXAFP or DEXP&A&N with MRI at different time points. h Measurement of tumor size in orthotopic HCC mice at 28 days after priming (n = 5; one-way ANOVA post hoc Student–Newman–Keuls test). i Flow cytometric and quantitative analysis of AFP+ tetramer T cells from tumor of orthotopic HCC mice treated with DEXAFP or DEXP&A&N (n = 5; one-way ANOVA post hoc Student–Newman–Keuls test). *p < 0.05, **p < 0.001; n.s, not significant